Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| No statute on record | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, THEODORE R | 1 | 66.8% | +25.4% |
| CHANDRA, GYAN | 1 | 71.1% | +27.7% |
| BREEN, KIMBERLY CATHERINE | 1 | 26.0% | +58.6% |
| SWIFT, CANDICE LEE | 1 | 58.3% | +38.5% |
| GURLEY, JAMI MICHELLE | 1 | 45.0% | +25.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037218 | TREATMENT OR PREVENTION OF A DISEASE OR DISORDER | BREEN, KIMBERLY CATHERINE | 53d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18459394 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | CHANDRA, GYAN | 18d overdue |
| 18565725 | FUSED HETEROCYCLIC DERIVATIVES | HOWELL, THEODORE R | 10d overdue |
| 17596538 | Recombinant Interleukin 12 Construct and Uses Thereof | GURLEY, JAMI MICHELLE | 21d |
| 18037204 | TREATMENT OR PREVENTION OF HIV INFECTION | SWIFT, CANDICE LEE | 26d |
| 18037218 | TREATMENT OR PREVENTION OF A DISEASE OR DISORDER | BREEN, KIMBERLY CATHERINE | 53d |
| Art Unit | Apps |
|---|---|
| 1657 | 2 |
| 1628 | 1 |
| 1674 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18565725 | FUSED HETEROCYCLIC DERIVATIVES | HOWELL, THEODORE R | 1628 | §112 | Non-Final OA | 10d overdue | Pending | Nov 30, 2023 |
| 18459394 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | CHANDRA, GYAN | 1674 | Other | Non-Final OA | 18d overdue | Pending | Aug 31, 2023 |
| 18037218 | TREATMENT OR PREVENTION OF A DISEASE OR DISORDER | BREEN, KIMBERLY CATHERINE | 1657 | Other | Final Rejection | 53d | Pending | May 16, 2023 |
| 18037204 | TREATMENT OR PREVENTION OF HIV INFECTION | SWIFT, CANDICE LEE | 1657 | Other | Final Rejection | 26d | Pending | May 16, 2023 |
| 17596538 | Recombinant Interleukin 12 Construct and Uses Thereof | GURLEY, JAMI MICHELLE | 1647 | §103 | Final Rejection | 21d | Pending | Dec 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial